Welcome to This Week in Dermatology. This week we are covering five notable papers spanning therapeutic advances and laboratory monitoring in alopecia areata, demographic variations in contact allergen sensitivities, multidimensional success metrics in hidradenitis suppurativa, and a critical update to the global naming system for biological therapies. Let's dive in. We begin with major clinical…

This week's papers:

Clinical Yield of Laboratory Monitoring During Ritlecitinib Treatment for Alopecia Areata: A Prospective Real-World Cohort Study — Journal of the American Academy of Dermatology 2026
The Association of Race and Ethnicity with Patch Test Results: North American Contact Dermatitis Group Data, 2007-2020 — Journal of the American Academy of Dermatology 2026
Long-term Efficacy and Safety of Upadacitinib in the Treatment of Alopecia Areata: A Retrospective Study — Journal of the American Academy of Dermatology 2026
Measuring success in HS treatment from the physician's and the patient's perspective — Journal of the European Academy of Dermatology and Venereology 2026
Decoding Biological Drug Names in Dermatology: The Post-2022 WHO Nomenclature Revision and Its Implications for Clinical Practice — Journal of the American Academy of Dermatology 2026